[ad_1] Compared to DPP-IV inhibitors, SGLT2 inhibitor empagliflozin was badociated with a 44% reduction in the relative risk of hospitalization for heart failure in people with type 2 diabetes with and without …
Read More »Empagliflozin reduces the number of hospitalizations related to heart failure in type 2 diabetes in the real world
